NASDAQ:DXCM - DexCom Stock Price, Forecast & News

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom, Inc. (NASDAQ:DXCM) released its quarterly earnings data on Wednesday, November, 6th. The medical device company reported $0.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.45. The medical device company earned $396.30 million during the quarter, compared to analyst estimates of $348.99 million. DexCom had a negative net margin of 12.68% and a positive return on equity of 16.16%. DexCom's quarterly revenue was up 48.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.17 EPS. View DexCom's Earnings History.

DexCom is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for DexCom.

DexCom will be holding an earnings conference call on Thursday, February 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

DexCom updated its fourth quarter 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $457-457 million, compared to the consensus revenue estimate of $431.47 million.

15 brokers have issued 12 month target prices for DexCom's shares. Their forecasts range from $125.00 to $255.00. On average, they anticipate DexCom's stock price to reach $207.43 in the next twelve months. This suggests that the stock has a possible downside of 10.1%. View Analyst Price Targets for DexCom.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DexCom.

Media headlines about DXCM stock have trended somewhat positive on Monday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. DexCom earned a news impact score of 1.7 on InfoTrie's scale. They also assigned media headlines about the medical device company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for DexCom.

Some companies that are related to DexCom include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Paypal (PYPL), Netflix (NFLX), Home Depot (HD), ServiceNow (NOW), Micron Technology (MU), Veeva Systems (VEEV) and Adobe (ADBE).

DexCom's stock is owned by many different of retail and institutional investors. Top institutional investors include Chicago Capital LLC (0.21%), Peregrine Capital Management LLC (0.10%), Patten & Patten Inc. TN (0.02%), Johanson Financial Advisors Inc. (0.01%), Gateway Investment Advisers LLC (0.01%) and DNB Asset Management AS (0.01%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Eric Topol, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for DexCom.

DXCM stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Tocqueville Asset Management L.P., Gateway Investment Advisers LLC, Chicago Capital LLC, Nisa Investment Advisors LLC, CenturyLink Investment Management Co, Patten & Patten Inc. TN and OLD National Bancorp IN. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman and Steven Robert Pacelli. View Insider Buying and Selling for DexCom.

DXCM stock was bought by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., DNB Asset Management AS, Assenagon Asset Management S.A., HWG Holdings LP, IFM Investors Pty Ltd, Zeke Capital Advisors LLC, Huntington National Bank and BKD Wealth Advisors LLC. View Insider Buying and Selling for DexCom.

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DXCM stock can currently be purchased for approximately $230.79.

DexCom has a market capitalization of $21.12 billion and generates $1.03 billion in revenue each year. The medical device company earns $-127,100,000.00 in net income (profit) each year or $0.30 on an earnings per share basis. DexCom employs 2,800 workers across the globe.View Additional Information About DexCom.

The official website for DexCom is http://www.dexcom.com/.

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]